ArticleBMJ open2022

Protocol for a phase 3 trial to evaluate the effectiveness and safety of a heterologous, two-dose vaccine for Ebola virus disease in the Democratic Republic of the Congo.

Deborah Watson-Jones et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.